Endometrial Cancer therapeutics market is poised to reach approximately US$ 27 Billion by 2023

Endometrial Carcinoma is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. According to the American Cancer Society, endometrial cancer is also the most common cancer of the female reproductive organs in the US. About 60,050 new cases of cancer of uterus were estimated to be diagnosed during 2016, and about 10,470 women died from cancers of the uterine body during the same year.Early detection of endometrial cancer helps in the selection of proper treatment options.

Browse full research report with TOC on "Global Endometrial Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Radiation Therapy, Surgery), By Enduser (Research Institutes, Hospitals & Clinics), & Pipeline Analysis, Outlook to 2023" At >>>> http://www.radiantinsights.com/research/global-endometrial-cancer-therapeutics-market

Endometrial Cancer can be treated by one or combination of therapies, such as chemotherapy, radiation therapy, hormone therapy, and surgery. Most of the physicians generally recommend combination treatments because chemotherapy alone has conventionally been deemed ineffective. Furthermore, adjuvant radiation therapy is ideal in patients who have diagnosed with Stage I or II endometrial cancer. Radiation Therapy is also recommended in patients who have undergone the surgery to avoid the relapse of endometrial cancer.

According to the RNCOS report entitled “Global Endometrial Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Radiation Therapy, Surgery), By Enduser (Research Institutes, Hospitals & Clinics), & Pipeline Analysis, Outlook to 2023”, the Endometrial Cancer therapeutics market is poised to reach approximately US$ 27 Billion by 2023. In this report, there is in-depthmarket analysis as well as market segmentation of global endometrial cancer therapeutics. The market potential of endometrial cancer therapeutic drugsisestimated considering that these are being tested in clinical trials for endometrial cancer, besides the ones which have already been approved. The depictedendometrial cancer therapeutic drugsare expected to show their complete market potential soon in the coming years.

Download request sample @ http://www.radiantinsights.com/research/global-endometrial-cancer-therapeutics-market/request-sample

Furthermore, in this report we have structured the information on epidemiology of endometrial cancer in the world. The report also covers pipeline analysis of endometrial cancer therapeutic drugs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments,as well as strategic collaborations that can impact industry’s growth.

In the end, the report enlists some of the key players in the Endometrial Cancer Therapeutics market including business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses.Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Table of Content

1. Analyst View

2. Research Methodology

3. Endometrial Cancer - Epidemiology & Risk Factors

4. Endometrial Cancer Therapeutics - An Introduction

5. Market Dynamics
5.1 Drivers
5.1.1 Rising Global Endometrial Cancer Epidemics
5.1.2 Obesity Fuelling Endometrial Cancer Incidences
5.1.3 Increasing Healthcare Expenditure
5.2 Challenges
5.2.1 High Cost Associated with the Treatment
5.2.2 Increasing Stringency in Regulatory Requirements

6. Endometrial Cancer Therapeutics Market Outlook to 2023
6.1 Market Potential

7. Market Segmentation
7.1 By Therapy
7.1.1 Chemotherapy
7.1.2 Hormonal Therapy
7.1.3 Radiation Therapy
7.1.4 Surgery
7.2 By End Users
7.2.1 Research Institutes & CROs
7.2.2 Hospitals & Clinics
7.3 By Geography
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World

8. Endometrial Cancer Therapeutic Drugs Pipeline Analysis
8.1 By Industry
8.1.1 By Clinical Phase
8.2 By Research Collaborations
8.2.1 By Clinical Phase

9. Trends and Developments
9.1 Womb Lining Models for further Endometriosis Investigation
9.2 Whole Exome Sequencing Aiding Identification of Targeted Therapies
9.3 Sentinel Lymph-node Mapping: Less Invasive Method for Staging
9.4 Metformin Holds Promise for Treating Endometrial Cancer
9.5 Adjuvant Chemotherapy Feasible for High Risk Endometrial Cancer

10. Strategic Mergers & Collaborations in the Endometrial Cancer Therapeutics Industry

11. Competitive Assessment
11.1 Bayer AG
11.2 F. Hoffman La Roche Ltd.
11.3 Bristol-Myers Squibb Company
11.4 Merck KGaA
11.5 Novartis AG
11.6 Takeda Pharmaceutical Company Limited
11.7 Eli Lilly and Company
11.8 Sanofi
11.9 GlaxoSmithKline plc
11.10 ArQule, Inc.

we focus on providing region specific information, in order for our clients to obtain maximum clarity on a granular level and make informed strategic decisions. Our reports generally encompass the following regional markets:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Argentina, Chile, Peru)
• Europe (Germany, UK, France, Greece, Italy, Spain, Czech Republic, Sweden, Netherlands, Norway, Denmark, Finland, Austria, Switzerland, Belgium)

Browse latest trending reports,

Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Clinical Trial Assessment & Pipeline Analysis (By Phase, Geography, and Key Player) Outlook 2022 @ http://www.radiantinsights.com/research/global-duchenne-muscular-dystrophy-therapeutics-market

28 2nd Street, Suite 3036, San Francisco, CA 94105, United States

Tel : 1-415-349-0054

Toll Free: 1-888-928-9744

Mail: sales@radiantinsights.com

This release was published on openPR.